Physician profile
Jeffrey Chen
NPI 1205906849
$1,199.96
in general payments reported to CMS, 2019-2025
22 companies · $84.24 in 2025
The $84.24 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $441 · 2020: $30.92 · 2022: $85.83 · 2023: $29.57 · 2024: $528 · 2025: $84.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $641.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $191.59 | 2019-2024 | |
| Janssen Biotech, INC. | $176.12 | 2019-2024 | Rybrevant |
| Edwards Lifesciences Corporation | $134.63 | 2019 | |
| Pfizer INC. | $102.26 | 2019-2024 | |
| Sobi, INC | $79.48 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $69.15 | 2024-2025 | Keytruda, Lynparza |
| Elekta, INC. | $67.50 | 2024 | Elekta Medical Linear Accelerator |
| Daiichi Sankyo INC. | $58.90 | 2023-2024 | Enhertu |
| Astellas Pharma US INC | $37.71 | 2019 | |
| Amgen INC. | $32.97 | 2019 | |
| Eisai INC. | $32.07 | 2024 | |
| Karyopharm Therapeutics INC. | $29.95 | 2024-2025 | Xpovio |
| Siemens Medical Solutions USA, INC. | $26.40 | 2024 | Truebeam |
| Stemline Therapeutics INC. | $22.99 | 2024 | Orserdu |
| Progenics Pharmaceuticals, INC. | $21.80 | 2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $20.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.73 | 2024 | |
| Aveo Pharmaceuticals, INC. | $19.55 | 2025 | |
| Novartis Pharmaceuticals Corporation | $16.32 | 2024 | |
| Azurity Pharmaceuticals, INC. | $16.11 | 2024 | Vivimusta |
| Dendreon Pharmaceuticals LLC | $13.00 | 2019 | |
| Ferring Pharmaceuticals INC. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.